In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

Data from Vista Health, a leading UK provider of private diagnostic services, has revealed the worrying knowledge gap when it comes to the prostate, as 26 percent of men do not know what their ...

This article was reviewed by Knox Beasley. Key Takeaways: 1mg oral finasteride effectively treats hair loss and is the ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

For patients with prostate cancer, concurrent use of enzalutamide, apalutamide, or abiraterone with direct oral antico ...

Cast urge men to get checked for prostate cancer.

If you really want to knock out for eight hours of uninterrupted bliss, the best sleep aid isn’t in your medicine cabinet — it’s in your nightstand. Put down the melatonin and pick up a vibrator, ...

A surgeon in London has carried out what is being described as the United Kingdom’s first long-distance robotic operation on a patient located approximately 1,500 miles (2,400km) away. Professor ...

Former ET co-host John Tesh revealed he that he far exceeded the wildest expectations of doctors who diagnosed him with cancer more than a decade ago - but he still lives with the disease.

Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from a late-stage trial of its experimental prostate cancer therapy.

Telix Pharmaceuticals Limited TLX shares are up during Tuesday’s premarket session following the announcement that Part 1 of the ProstACT Global Phase 3 study achieved its primary objectives. The ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...